Researchers reported new molecular insights into C5aR2, a complement receptor that signals in ways that depart from classical expectations, adding clarity to how the complement pathway regulates inflammation. The story explains that C5aR2 operates in tandem with C5aR1 to mediate effects of C5a, an anaphylatoxin implicated in inflammatory signaling. By detailing unique signaling features and agonists for C5aR2, the work aims to resolve longstanding uncertainty around the receptor’s mechanisms. For drug discovery teams, complement receptors remain a major therapeutic target class in inflammation and immune-mediated disease. This finding narrows mechanistic ambiguity—an input that can influence target validation, biomarker strategy, and agonist/antagonist screening.